Alembic Pharmaceuticals Limited (APLLTD) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.076x

Based on the latest financial reports, Alembic Pharmaceuticals Limited (APLLTD) has a cash flow conversion efficiency ratio of 0.076x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs4.03 Billion ≈ $43.57 Million USD) by net assets (Rs53.16 Billion ≈ $574.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Alembic Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Alembic Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Alembic Pharmaceuticals Limited (APLLTD) total liabilities for a breakdown of total debt and financial obligations.

Alembic Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Alembic Pharmaceuticals Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
C&S Paper Co Ltd
SHE:002511
0.142x
IBI Inv House
TA:IBI
0.094x
Shenzhen Noposion Agrochemicals Co Ltd
SHE:002215
-0.063x
IReader Technology Co Ltd
SHG:603533
-0.031x
HBIS Resources Co Ltd
SHE:000923
0.009x
Beijing Lier High Temperature Materials Co Ltd
SHE:002392
0.010x
BlackRock Science and Technology Trust II
NYSE:BSTZ
-0.009x
Interface Inc
NASDAQ:TILE
0.041x

Annual Cash Flow Conversion Efficiency for Alembic Pharmaceuticals Limited (2011–2025)

The table below shows the annual cash flow conversion efficiency of Alembic Pharmaceuticals Limited from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Alembic Pharmaceuticals Limited.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs51.90 Billion
≈ $561.23 Million
Rs879.70 Million
≈ $9.51 Million
0.017x -89.83%
2024-03-31 Rs48.18 Billion
≈ $521.07 Million
Rs8.03 Billion
≈ $86.86 Million
0.167x +0.64%
2023-03-31 Rs43.70 Billion
≈ $472.65 Million
Rs7.24 Billion
≈ $78.29 Million
0.166x +57.07%
2022-03-31 Rs52.38 Billion
≈ $566.42 Million
Rs5.52 Billion
≈ $59.73 Million
0.105x -63.48%
2021-03-31 Rs50.67 Billion
≈ $547.97 Million
Rs14.63 Billion
≈ $158.26 Million
0.289x +105.16%
2020-03-31 Rs31.90 Billion
≈ $345.04 Million
Rs4.49 Billion
≈ $48.57 Million
0.141x -52.88%
2019-03-31 Rs27.18 Billion
≈ $293.94 Million
Rs8.12 Billion
≈ $87.81 Million
0.299x +112.32%
2018-03-31 Rs22.20 Billion
≈ $240.13 Million
Rs3.12 Billion
≈ $33.79 Million
0.141x -7.37%
2017-03-31 Rs19.01 Billion
≈ $205.61 Million
Rs2.89 Billion
≈ $31.23 Million
0.152x -73.87%
2016-03-31 Rs16.01 Billion
≈ $173.09 Million
Rs9.30 Billion
≈ $100.62 Million
0.581x +199.39%
2015-03-31 Rs8.85 Billion
≈ $95.67 Million
Rs1.72 Billion
≈ $18.58 Million
0.194x -44.47%
2014-03-31 Rs6.76 Billion
≈ $73.06 Million
Rs2.36 Billion
≈ $25.55 Million
0.350x -33.59%
2013-03-31 Rs5.03 Billion
≈ $54.39 Million
Rs2.65 Billion
≈ $28.64 Million
0.527x +47.78%
2012-03-31 Rs3.95 Billion
≈ $42.72 Million
Rs1.41 Billion
≈ $15.22 Million
0.356x +9.39%
2011-03-31 Rs2.95 Billion
≈ $31.93 Million
Rs961.81 Million
≈ $10.40 Million
0.326x --

About Alembic Pharmaceuticals Limited

NSE:APLLTD India Drug Manufacturers - Specialty & Generic
Market Cap
$1.60 Billion
Rs148.41 Billion INR
Market Cap Rank
#7108 Global
#323 in India
Share Price
Rs755.00
Change (1 day)
-0.80%
52-Week Range
Rs646.55 - Rs1039.10
All Time High
Rs1247.70
About

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal healt… Read more